Roxybond (Oxycodone HCl) Patent Expiration, LOE Window & CMS Spending
Roxybond (Oxycodone HCl) by Protega: FDA Orange Book LOE 2028-08-12, 11 AB generics, $3.0M 2024 CMS Part D & Medicaid spend, and 12 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Protega |
| FDA Application & Pathway | N209777 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2028-08-12 |
| Orange Book Patents (*PED Extensions) | 2 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 11 |
| 2024 CMS Total Public Spend | $3.0M |
| 2024 Medicare Part D Spend | $2.2M |
| 2024 Medicaid Spend | $783K |
| Reported Wholesale Price Change (CA SB 17) | 12 WAC filings (max 32.9% 2-yr change) |